Nintedanib

Ofev, Vargatef (nintedanib) is a small molecule pharmaceutical. Nintedanib was first approved as Ofev on 2014-10-15. It is used to treat idiopathic pulmonary fibrosis in the USA. It has been approved in Europe to treat idiopathic pulmonary fibrosis and non-small-cell lung carcinoma. The pharmaceutical is active against vascular endothelial growth factor receptor 3. In addition, it is known to target platelet-derived growth factor receptor beta, vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor alpha, fibroblast growth factor receptor 4, vascular endothelial growth factor receptor 1, fibroblast growth factor receptor 3, fibroblast growth factor receptor 1, and fibroblast growth factor receptor 2. Ofev's patents are valid until 2029-06-07 (FDA).